{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-076672","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.452109+00:00","generated_at":"2026-05-17T13:46:33.933047+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M","bullets":["Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.","Loss from operations $0.4M vs income of $0.6M in prior year.","Net loss $1.1M ($0.02/share) vs $2.2M ($0.03/share) in Q2 2024; decrease due to lower other expense.","Cash balance $0.9M at June 30, 2025, down from $1.4M at year-end 2024.","Operating expenses reduced 33% to $3.0M, primarily from headcount reduction in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-076672","json":"https://secwatch.observer/filing/0001213900-25-076672.json","markdown":"https://secwatch.observer/filing/0001213900-25-076672.md","text":"https://secwatch.observer/filing/0001213900-25-076672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390025076672/0001213900-25-076672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390025076672/ea0253040-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:46:33.933047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}